Detalhe da pesquisa
1.
Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
Xenobiotica
; 46(5): 445-56, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26340566
2.
Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity.
J Pharmacol Exp Ther
; 354(2): 225-9, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26062557
3.
The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys.
Xenobiotica
; 45(1): 60-70, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034010
4.
Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic.
Drug Metab Dispos
; 41(5): 1070-81, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23439661
5.
Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.
Drug Metab Dispos
; 40(1): 139-50, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21965624
6.
Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
Drug Metab Dispos
; 40(11): 2090-101, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22851617
7.
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.
J Acquir Immune Defic Syndr
; 72(4): 400-7, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26974526
8.
Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys.
J Med Chem
; 46(12): 2502-15, 2003 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-12773054
9.
Metabolite structure analysis by high-resolution MS: supporting drug-development studies.
Bioanalysis
; 5(4): 463-79, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23414379
10.
Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes.
Clin Pharmacol Drug Dev
; 2(3): 213-22, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27121782